Department：Gastroenterology
Medical School：Zhejiang University School of Medicine, China
Academic Rank：Chief Technician
Study on the molecular mechanism of gastrointestinal cancer and gastrointestinal cancer stem cells; helicobacter pylori detection and molecular pathogenesis (carcinogenesis) mechanism research.
Zhejiang Scientific and Technological Progress Award, Third Prize
Associate Director, Zhejiang Key Laboratory of Tumor Microenvironment and Immunotherapy, 2019-present
Associate Director, Zhejiang Society of Clinical Immunology, 2018- present
Director, Zhejiang Society of Immunology, 2018- present
Editorial Board Member, World Journal of Gastrointestinal Pathophysiology, 2018- present
Editorial Board Member, World Journal Gastrointestinal Endoscopy, 2018- present
Editorial Board Member, World Chinese Journal of Digestology, 2018- present
Based on human primary PDX models, organoid cultures, and virus libraries, Dr. Zhu's team has identified three new proteins in previous studies that have been shown to promote mitochondrial metabolic reprogramming in CRC cells—ANKRD22, ARRDC4, and FAM227A. Studies on the molecular mechanism suggest that metabolic reprogramming plays a key role in the tumor microenvironment inducing common tumor cells to regenerate initialing cell characteristics. The discovery of these molecules and targeted intervention is an important way to block the regeneration of CRC initiating cells. At present, Dr. Zhu's team intends to systematically screen reprogramming-related key mitochondrial proteins of CRC cells regulated by microenvironment by comparing mass spectrometric differences and high-throughput screening platforms in vitro; investigate the effects of these target proteins on mitochondrial autophagy, energy metabolism and ability to regenerate initialing cell characteristics. Dr. Zhu's research may lay a solid foundation for the development of new low-toxicity molecular drugs targeting tumor initiating cells in the future.
Pan TH, Liu JW, Xu S, Yu Q, Wang HP, Sun HX, Wu J, Zhu Y, Zhou JW*, Zhu Y*. ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells. Theranostics. 2020, 10: 516-536.
Wen Z, Xu S, Jiang Q, Zhu L, Feng S, Zhao Y, Wu J, Dong Q, Mao J*, Zhu Y*. Interaction between NRIP2 and ROR, a novel mechanism, involved in the self-renewal of tumor-intiating cell of colorectal cancer. Molecular Cancer. 2017, 16: 20.
Pan T, Xu J, Zhu Y*. Self-renewal molecular mechanisms of colorectal cancer stem cells. Int J Mol Med. 2017, 39: 9-20.
Xu S, Wen ZZ, Feng S, Zhu L, Mao J, Cai J, Zhu Y*. CD58, a novel surface marker, promotes self-renewal of tumor-intiating cells in colorectal cancer. Oncogene 2015, 34, 1520-1531.
Wu J, Pan TH, Xu S, Jia LT, Zhu LL, Mao JS, Zhu YL*, Cai JT. The virus-induced protein APOBEC3G inhibits anoikis by activation of Akt kinase in pancreatic cancer cells. Sci Rep. 2015;5:12230.
Wu J, Ji X, Zhu Y*. Up-regulation of microRNA -1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Letters 2013, 329:155-163.
Wu J, Xu S, Zhu Y*. Helicobacter pylori CagA: a critical destroyer of the gastric epithelial barrier. Dig Dis Sci. 2013, 58:1830-1837.
Zhu Y*, Jiang Q, Lou X, et al. MicroRNAs up-regulated by CagA of Helicobacter pylori induce intestinal metaplasia of gastric epithelial cells. PLoS One. 2012, 7:e35147.
Tao H, Zhu Y*. Colorectal cancer stem cell: a potential therapeutic target. Clin Transl Oncol. 2011, 13:833-838.
Wang Y#, Zhu Y#, Qiu F, Zhang T, Chen Z, Zheng S, Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis. 2010, 31:1376-13780.
Research on new technology of immunity, cell and gene therapy-research and development of new human tumor micaα3 nano mAb and evaluation of its anti-metastasis effect. Funding Source: Key R&D Project of Zhejiang Provincial Department of Science and Technology.
Identification of new mitochondrial reprogramming target and molecular mechanism of FAM227A in promoting colorectal cancer cells to regain the characteristics of stem cells. Funding Source: National Natural Science Foundation of China.
Identification of key targets and molecular mechanism of ARRDC4 involved in the reprogramming of colorectal cancer cells induced by tumor microenvironment. Funding Source: National Natural Science Foundation of China.
Identification of key targets and molecular mechanism of ANKRD22 involved in the reprogramming of colorectal cancer cells. Funding Source: National Natural Science Foundation of China.
New adjuvant anti-tumor peptide vaccine. Funding Source: National Science and Technology Major Projects.
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
